## KEY TAKEAWAYS
- **Korsana Biosciences emerged from stealth on February 18, 2026, securing $175 million in Series A venture funding to develop KRSA-028, a novel antibody treatment for Alzheimer's disease targeting amyloid-beta buildup.**
- **KRSA-028 targets a significant clinical gap: existing approved therapies (Eli Lilly's Kisunla and Eisai/Biogen's Leqembi) carry safety warnings including brain swelling and micro-bleeds, plus impose high treatment burdens requiring frequent intravenous infusions.**
- **The company's competitive advantage centers on improved blood-brain barrier penetration using proprietary technology, enabling less frequent subcutaneous administration—a delivery mechanism analysts believe could drive superior patient uptake versus existing options.**
- **Korsana's lead program builds on intellectual property originally developed by hub-and-spoke biotech Paragon Therapeutics, positioning the startup within a broader wave of venture-backed neurodegenerative disease programs.**
- **The $175 million raise reflects investor confidence in a crowded but expanding Alzheimer's therapeutics market, where pharma-backed venture initiatives have collectively mobilized over $500 million for dementia drug development.**
## DETAILED SUMMARY
Korsana Biosciences, a Novato-based biotechnology startup, officially announced its emergence from stealth mode on February 18, 2026, with $175 million in Series A venture capital funding. The company is developing KRSA-028, a monoclonal antibody designed to address amyloid-beta accumulation in the brain—the hallmark pathological feature of Alzheimer's disease. The capital infusion positions Korsana to advance clinical development of its lead program while building out a broader pipeline focused on neurodegenerative conditions.
The startup's therapeutic approach enters a market recently validated by two FDA-approved disease-modifying treatments: Eli Lilly's Kisunla and the jointly developed Leqembi (Eisai and Biogen). However, both existing therapies carry significant clinical and logistical limitations. Both carry safety warnings regarding amyloid-related imaging abnormalities (ARIA)—including brain swelling and microhemorrhages—and deliver only modest efficacy gains. Leqembi requires 18 months of intravenous infusions before patients can transition to weekly subcutaneous dosing, while Kisunla remains intravenous-only. These limitations create a substantial unmet need that Korsana's founders believe their technology can address.
Korsana's competitive strategy centers on overcoming the blood-brain barrier, a historically intractable challenge in neurodegenerative drug development. Most monoclonal antibodies struggle to cross this barrier efficiently, limiting drug penetration and requiring higher doses that increase adverse event risk. The company's proprietary approach aims to improve penetration across the barrier while enabling less frequent dosing via subcutaneous administration. Wall Street analysts have previously identified subcutaneous delivery frequency as a key driver of patient compliance and commercial success for Alzheimer's therapeutics.
The company's intellectual property foundation includes a treatment program originally developed by Paragon Therapeutics, a hub-and-spoke biotech model company. Jonathan Violin, Korsana's president and CEO, articulated the company's mission in stark terms: "Only two disease-modifying therapies have been approved to treat Alzheimer's, and both carry safety warnings, offer only modest efficacy, and impose a high burden of care. Patients deserve better options than what is currently available."
The $175 million Series A round signals sustained institutional investor appetite for next-generation Alzheimer's therapeutics. This funding event occurs within a broader venture capital mobilization around dementia treatment, with pharma-backed venture funds and independent venture investors collectively committing over $500 million to dementia-focused biotech initiatives in recent years. The successful capitalization of Korsana suggests investor confidence that meaningful clinical and commercial differentiation remains achievable despite recent approvals, particularly for candidates addressing safety and dosing burden limitations inherent in current standard-of-care options.
